The CRISPR/Cas9 (CRISPR-associated protein 9 nuclease) system uses a RNA-guided endonuclease technology which allows for inducing indel mutations, specific sequence replacements or insertions and large deletions or genomic rearrangements at any desired location in the genome. In addition, Cas9 can also be used to mediate up- or downregulation of specific endogenous genes or to alter histone modifications or DNA methylation.
Diagenode now offers the first antibody against CRISPR/Cas9 on the market. This antibody has been raised against Cas9 from Streptococcus pyogenes and gives excellent results in all major applications (immunoblot, immunoprecipitation, and immunofluorescence). The new antibody allows for the monitoring of CRISPR/Cas9 experiments. For example, the antibody can be used for ChIP followed by sequencing to determine whether Cas9 is targeting the sequence of interest.